Effect of resveratrol on the formation of intracranial aneurysms and telomere length

doi:10.3877/cma.j.issn.2095-9141.2019.05.009

Abstract

Abstract:

Objective

To investigate the effects of resveratrol on the formation of intracranial aneurysm (IA) and telomere length in rats.

Methods

Thirty-six SD rats were randomly divided into control group (n=12), IA group (n=12) and resveratrol group (n=12). Rats in IA group and resveratrol group were used to construct IA rat model. According to the dose of 40 mg/kg, resveratrol was dissolved in 2 mL saline and given intragastrically in the resveratrol group rats, and 2 mL saline was given to the rats in the IA group every day, and no additional operation was performed in the control group. After 12 weeks, the relative length of telomere and the relative expression of telomerase reverse transcriptase (TERT) and telomere binding protein-tripeptidase 1 (TPP1) were measured by real-time PCR, and the formation of IA was observed by scanning electron microscope after vascular casting.

Results

There was no significant difference in the formation rate of IA between resveratrol group and IA group (75.0% vs 66.7%, P>0.05), but the formation rate of stage Ⅲ aneurysm in resveratrol group was significantly lower than that in IA group (χ²=4.800, P=0.028). The telomere length and the expression of TERT and TPP1 in IA group and resveratrol group were significantly lower than those in control group(P<0.05). Compared with IA group,resveratrol group had longer telomere length and higher expression of TERT and TPP1 (P<0.05).

Conclusion

Resveratrol has no effect on the formation of IA, but can inhibit the shortening of telomere length and delay the progress of IA.

Key words: Intracranial aneurysm, Resveratrol, Telomere

Zhili Xu, Sai Zhang, Yue Tu, Huancheng Wu, Yang Liu. Effect of resveratrol on the formation of intracranial aneurysms and telomere length[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2019, 05(05): 295-298.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2019.05.009

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2019/V05/I05/295

Figures/Tables 3

References 19

[1]	Juvela S,Poussa K,Lehto H, et al. Natural history of unruptured intracranial aneurysms: a long-term follow-up study[J]. Stroke, 2013, 44(9): 2414-2421.
[2]	Vlak MH,Algra A,Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis[J]. Lancet Neurol, 2011, 10(7): 626-636.
[3]	付浩,孙圣凯,陈孝储,等.高血压大鼠线粒体DNA拷贝数与端粒长度的相关性研究[J].中国医药导报, 2016, 13(31): 33-36.
[4]	Rasmussen K,Møller J. Total homocysteine measurement in clinical practice[J]. Ann Clin Biochem, 2000,37 (Pt5): 627-648.
[5]	梁海乾,李晓红,王景景,等.沉默调节蛋白1促进体外神经元的轴突生长[J].中国神经精神疾病杂志, 2014, 40(6): 321-324.
[6]	Eldawoody H,Shimizu H,Kimura N, et al. Simplified experimental cerebral aneurysm model in rats: comprehensive evaluation of induced aneurysms and arterial changes in the circle of Willis[J]. Brain Res, 2009, 1300(11): 159-168.
[7]	D’Mello MJ,Ross SA,Briel M, et al. Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis[J]. Circ Cardiovasc Genet, 2015, 8(1): 82-90.
[8]	Zhan Y,Hägg S. Telomere length and cardiovascular disease risk[J]. Curr Opin Cardiol, 2019, 34(3): 270-274.
[9]	Tian Y,Wang S,Jiao F, et al. Telomere length: a potential biomarker for the risk and prognosis of stroke[J]. Front Neurol, 2019, 10(4): 624-633.
[10]	Kataoka H. Molecular mechanisms of the formation and progression of intracranial aneurysms[J]. Neurol Med Chir (Tokyo), 2015, 55(3): 214-229.
[11]	Sadasivan C,Fiorella DJ,Woo HH, et al. Physical factors effecting cerebral aneurysm pathophysiology[J]. Ann Biomed Eng, 2013, 41(7): 1347-1365.
[12]	Townsley DM,Dumitriu B,Liu D, et al. Danazol treatment for telomere diseases[J]. N Engl J Med, 2016, 374(20): 1922-1931.
[13]	朱淑英.健康人外周血白细胞端粒长度与衰老相关性研究[D].南昌:南昌大学, 2013.
[14]	Zhong FL,Batista LF,Freund A, et al. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends[J]. Cell, 2012, 150(3): 481-494.
[15]	Guo X,Deng Y,Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis[J]. EMBO J, 2007, 26(22): 4709-4719.
[16]	Jose SS,Bendickova K,Kepak T, et al. Chronicinflammation in immune aging: role of pattern recognition receptor crosstalk with the telomere complex?[J]. Front Immunol, 2017, 8(11): 1078.
[17]	Cheng SB,Davis S,Sharma S. Maternal fetal cross-talk through, cell-free fetal DNA, telomere shortening, microchimerism, and inflammation[J]. Am J Reprod Immunol, 2018, 79(5): e12851.
[18]	李方,曹建民,王传军,等.白藜芦醇通过调节SIRT1/NF-κB通路减轻力竭训练致大鼠肾的炎症反应[J].中国生物化学与分子生物学报, 2019, 22(7): 773-779.
[19]	赵丽,华夏,谭晔,等.基于Notch1信号通路探讨白藜芦醇对人结肠上皮细胞炎症损伤的保护作用[J].遵义医学院学报, 2018, 41(6): 695-699.

引物名称	引物序列（5 ’-3 ’）	终浓度(nmol/L)
TEL	上游：GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT	100
?	下游：TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA	900
TERT	上游：AGTGGTGAACTTCCCTGTGG	400
?	下游：CAACCGCAAGACTGACAAGA	400
TPP1	上游：CAGTGACCACCCAGGACTTT	400
?	下游：CAACAGGTCCCACTCCTTGT	400
GAPDH	上游：TACACTGAGGACCAGGTTG	400
?	下游：CCCTGTTGCTGTAGCCATA	400

引物名称	引物序列（5 ’-3 ’）	终浓度(nmol/L)
TEL	上游：GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT	100
?	下游：TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA	900
TERT	上游：AGTGGTGAACTTCCCTGTGG	400
?	下游：CAACCGCAAGACTGACAAGA	400
TPP1	上游：CAGTGACCACCCAGGACTTT	400
?	下游：CAACAGGTCCCACTCCTTGT	400
GAPDH	上游：TACACTGAGGACCAGGTTG	400
?	下游：CCCTGTTGCTGTAGCCATA	400

组别	只数	端粒长度	TERT	TPP1
对照组	12	0.98±0.14	1.09±0.14	1.02±0.16
IA组	12	0.47±0.04^a	0.36±0.07^a	0.65±0.09^a
白藜芦醇组	12	0.83±0.16^ab	0.63±0.07^ab	0.85±0.06^ab
F值	?	52.383	104.448	33.596
P值	?	<0.001	<0.001	<0.001

组别	只数	端粒长度	TERT	TPP1
对照组	12	0.98±0.14	1.09±0.14	1.02±0.16
IA组	12	0.47±0.04^a	0.36±0.07^a	0.65±0.09^a
白藜芦醇组	12	0.83±0.16^ab	0.63±0.07^ab	0.85±0.06^ab
F值	?	52.383	104.448	33.596
P值	?	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export